ESR1 and breast carcinoma: Luteolin and its glycosides, including LU8C-FP, mLU8C-PU, and orientin, have been reported as potential anticancer compounds in several breast cancer cell lines, including wild-type ER (+) MCF-7 cells (Kim et al., 2012[21], 2018[22][23]; Park et al., 2013[28]).